Introduction and Objective: Automated insulin delivery (AID) systems, adjusting insulin based on real-time glucose readings, may offer advantages over open-loop insulin delivery (OLID), especially during Ramadan fasting, which poses challenges for individuals with type 1 diabetes (T1D).Methods: This dual-center, open-label, randomized controlled trial compared AID systems (Medtronic MiniMed 780G [M780] and Tandem T-slim Control IQ [TCIQ]) with OLID systems (Medtronic MiniMed 640G or MiniMed VEO insulin pump with Guardian 3/4 sensors or Freestyle Libre sensors) in patients with T1D observing Ramadan. The primary outcome was the difference in Time in Range (TIR) during Ramadan. Secondary outcomes included Time Below Range (TBR), Time Above Range (TAR), and a composite outcome (TIR ≥ 70%, TBR < 5%, and ≤ 2 fast-broken days).Results: Baseline characteristics were similar between groups. The control group (N=55), M780 group (N=20) and TCIQ group (N=24) had average ages of 27.7 ± 6.0, 26.0 ± 9.6 years and 27.1 ± 6.1 years, respectively. Results are presented in the table below.Conclusion: M780 and TCIQ AID systems significantly enhanced glycemic control, patients safety, and adherence to religious practices during Ramadan, providing an effective solution for T1D management during fasting.
M. Almehthel: Advisory Panel; Novo Nordisk. Speaker’s Bureau; Novo Nordisk. Research Support; Novo Nordisk. Advisory Panel; Sanofi. Speaker’s Bureau; Sanofi. Research Support; Sanofi. Speaker’s Bureau; Lilly Diabetes. Advisory Panel; Abbott. Speaker’s Bureau; Abbott. Advisory Panel; Dexcom, Inc. Speaker’s Bureau; Bayer Pharmaceuticals, Inc. A. Alqahtani: None. N. Aboalsamh: None. I. Brema: None. M.M. Ahmad: None. N.A. Sharahili: None. A.E. Aljohani: None. S.H. Alzahrani: None. I.A. Alghofaili: None. M. Hassanein: None.
Source link
Leave a Reply